deltatrials
Active Not Recruiting PHASE2 NCT00003915

Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment

Sponsor: University of Massachusetts, Worcester

Conditions Prostate Cancer
Interventions bicalutamide docetaxel estramustine phosphate sodium leuprolide acetate
Updated 3 times since 2017 Last updated: Mar 1, 2017

This PHASE2 trial investigates Prostate Cancer and is currently ongoing. University of Massachusetts, Worcester leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

3 versions recorded

  1. Jun 2018 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Massachusetts, Worcester
Data source: University of Massachusetts, Worcester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Burlington, United States
  • • Lebanon, United States
  • • Worcester, United States